The American Society of Addiction Medicine (ASAM) and the American College of Medical Toxicology (ACMT) are seeking input from diverse stakeholders on the draft of their jointly developed Clinical Consensus Statement on Drug Testing in Substance Use Disorder Treatment. This document is intended to support clinicians in determining when, why, and how to apply drug testing in the identification of substance use and the clinical management of patients with substance use disorders or substance use related medical concerns.

The deadline to submit comments is June 30, 2026.

Instructions for Review

1. Download the draft document HERE

2. Provide Comments

This document will be professionally copyedited prior to finalization.

Comments will be collected through this survey to facilitate reconciliation of feedback. A preview of the survey can be found here. When providing your comments, please include the page and line number (not a range, just a single number) in the appropriate boxes. If your comment refers to a range of line numbers, you only need to indicate the first line number within the range. To make a general comment about the document as a whole, put 0 for page and line numbers. You can provide up to 100 comments. If you would like to provide additional comments, you can submit the survey again. Feedback must be submitted through this survey to be considered.

Note: The system does not allow you to save your progress to return later. Always submit your response before exiting. If you have additional comments at a later time, you can reenter the survey and submit a new response.

3. Complete a Disclosure form.
You will be redirected to a Disclosure form at the end of this survey. If you are a patient who wishes to remain anonymous, please provide a unique fake name on both this survey and the disclosure form (i.e., not John Doe). Please ensure the name is the same on both forms.

If you have any questions, please contact tsafarian@asam.org. Thank you in advance for your participation in this important initiative. We look forward to your feedback.